AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03743545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low speed drilling without irrigation
Description: comparing between conventional implant placement drilling speed with irrigation and experimental arm (low speed without irrigation)
Study NCT03743545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low speed drilling without irrigation
Description: comparing between conventional implant placement drilling speed with irrigation and experimental arm (low speed without irrigation)
Study NCT00781443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab (MILR1444A)
Description: Repeating subcutaneous injection
Study NCT00781443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Repeating subcutaneous injection
Study NCT03381664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923
Description: capsule
Study NCT02840279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN14770
Description: BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
Study NCT02840279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00870480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg Tablet, single dose
Description: A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
Study NCT00870480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proscar® 5 mg Tablet, single dose
Description: B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
Study NCT02994966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surrosense
Study NCT02994966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Study NCT01728285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic compliance device (Memozax®)
Description: An electronic compliance device is distributed to patients allocated to the active arm
Study NCT02780934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Dressing
Description: Patients in this group will receive the standard post-operative bandage: a pressure dressing consisting of high absorbency gauze and retention tape.
Study NCT02780934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple Adhesive Dressing
Description: Patients in this group will receive the experimental bandage: a simple adhesive dressing consisting of a non adherent pad and transparent dressing.
Study NCT01813695 — intervention group
Intervention type: PROCEDURE
Intervention: Preemptive genotyping in medical record
Study NCT01813695 — intervention group
Intervention type: PROCEDURE
Intervention: Genotyping not included in electronic medical record
Study NCT03110718 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ArmeoP+real MV
Description: All the subjects assigned to the experimental received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air (Vibraplus; @Circle, San Pietro in Casale, Italy) (fig. 2) wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude (approximately 2mm in indentation depth, mean pressure of 250mBar, which effectively induce inhibition of the monosynaptic reflex) so that it was just below the threshold for perceiving an illusory movement. We chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
Study NCT03110718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArmeoP+real MV
Description: All the subjects assigned to the experimental received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air (Vibraplus; @Circle, San Pietro in Casale, Italy) (fig. 2) wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude (approximately 2mm in indentation depth, mean pressure of 250mBar, which effectively induce inhibition of the monosynaptic reflex) so that it was just below the threshold for perceiving an illusory movement. We chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
Study NCT01984047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3050002
Description: GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.
Study NCT01984047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion
Study NCT02271893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
Study NCT02271893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan
Description: The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
Study NCT00664482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-006
Description: Autologous Therapy for Pancreatic Cancer
Study NCT00841061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: electrolytic iron
Description: 1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age
Study NCT00841061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ferrous fumarate
Description: 1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
Study NCT03847831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active School Flag Program
Description: Schools enrolled in the program take part in the 17 actions described in the PPASF.
Study NCT04451005 — intervention group
Intervention type: OTHER
Intervention: 0
Description: Elderly patients with sarcopenia
Study NCT04038294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ISOlution protein supplement
Description: EXPERIMENTAL ARM: Protein supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home.
Study NCT04038294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: PLACEBO COMPARATOR ARM: Placebo supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home
Study NCT04301323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHVI1 eye drops
Description: Including 35 children enrolled to receive BHVI1 eye-drops once nightly
Study NCT04301323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHVI2 eye drops
Description: Including 35 children enrolled to receive BHVI2 eye-drops once nightly
Study NCT04301323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHVI3 eye drops
Description: Including 35 children enrolled to receive BHVI3, combination of BHVI1 and BHVI2, eye-drops once nightly
Study NCT01749527 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: minimal activity
Description: Pad test with minimal activity
Study NCT02524561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEE pill
Description: Conjugated equine estrogens 0.45 mg/day
Study NCT02524561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol patch
Description: Climara 50 mcg/day
Study NCT02524561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Progesterone
Description: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Study NCT02524561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet
Study NCT02524561 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet
Study NCT02524561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch
Description: placebo patch
Study NCT02524561 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: placebo patch
Study NCT02524561 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo progesterone
Description: placebo progesterone
Study NCT00811720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: as-needed use, tablets, orally, 6 months
Study NCT00811720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: 18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
Study NCT02581436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kSORT assay based follow-up
Description: kSORT assay in pre-established days: 14, 45, 90, 180, 365 and 540 of post transplantation follow-up. If kSORT result is positive maintenance immunosuppressive will be increased (tacrolimus trough levels 12-15 ng/mL, Mofetil Mycophenolate 1.5 mg every 24 hours and prednisone 5 mg/day) and graft biopsy will be obtained. Kidney biopsy will be obtained one mo after treatment as well as kSORT assay. If kSORT result is negative, the maintenance immunosuppressor dosages will remain as established in our institutional guidelines. If after a year of follow-up, the kSORT result is negative, immunosuppression will be decreased (Tacrolimus levels 5 - 10 ng/ml and mofetil mycophenolate 500 mg every 12 hours).
Study NCT02581436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Surveillance will be the usual, includes creatinine determinations and clinical evaluation as often as established in the institutional protocol. A kidney graft biopsy will be obtained in case of dysfunction (increase in serum creatinine >25% above baseline or 0.3 mg/mL above baseline) or as part of our institutional programmed biopsies (months 3 and 12). Treatment will be established in accordance with biopsy results. In all cases of rejection a kidney biopsy will be obtained one month after initiating treatment. In this control group, samples for kSORT analysis will be collected on pre-established dates for the study, but patient treatment will not be contingent on the assay's results; investigators will be blinded to the result in this control patient group.
Study NCT01107067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustanon
Description: 250 mg/21 days
Study NCT03487016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Arm A
Study NCT03487016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Arm A
Study NCT03487016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Arm B Arm C
Study NCT03487016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposomal Injection
Description: Arm B Arm C
Study NCT03487016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Arm C
Study NCT02597530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
Study NCT02597530 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TEAS
Description: According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
Study NCT02597530 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TEAS
Description: According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
Study NCT03589287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chondrochymal®
Description: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells
Study NCT02701309 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive Iron detection device via Zinc-Protoporphyrin
Description: In this study the feasability, sensitivity and specifity of a non-invasive detection method of zinc-protoporphyrin in children is evaluated. It´s a one-arm study, without control Group. Children are aged between 9m and 5y and have a clinical blood sampling indicated.
Study NCT00737932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
Study NCT00737932 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo for 8 weeks of treatment
Study NCT03962959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TBS
Description: TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
Study NCT03962959 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TBS
Description: TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
Study NCT02365181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-articular local anesthetic infiltration
Description: intra-articular local anesthetic infiltration with 20 ml of Ropivacaine 2 % and catheter
Study NCT02365181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inter-scalene block
Description: inter-scalene block with 20 ml of Ropivacaine 2 % and catheter
Study NCT02365181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 %
Description: 20 ml of Ropivacaine 2 %
Study NCT02365181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 2 %
Description: 20 ml of Ropivacaine 2 %
Study NCT05101811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D Levels measurement using chemiluminescent assay
Description: Measurement of serum vitamin D levels
Study NCT05101811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitamin D level assessment
Description: Using lIAISON DEVICE
Study NCT01757301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assisted Symptom Management (ASM)
Description: There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
Study NCT01757301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Symptom Management (CSM)
Description: This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only).
Study NCT03954912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MAKO assisted unicondylar knee arthroplasty
Description: MAKO assisted
Study NCT03954912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NAVIO assisted unicondylar knee arthroplasty
Description: NAVIO assisted
Study NCT02356536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agilitas
Description: WCD trial
Study NCT02389465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram + Celecoxib
Description: Participants will receive celecoxib in addition to escitalopram
Study NCT02389465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram + Placebo
Description: Participants will receive a placebo in addition to escitalopram.
Study NCT02002988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endomyocardial BT injection
Study NCT03318445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: All participants will take rucaparib by mouth
Study NCT03318445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Patients in the dose escalation phase, and patients in the dose expansion phase who have received prior PARP inhibitor therapy, will be given irinotecan by in combination with rucaparib.
Study NCT01559545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Immediate release metronidazole 500 mg orally three times a day for 14 days
Study NCT01559545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole-DRF1
Description: Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
Study NCT01559545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole-DRF2
Description: Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
Study NCT03089047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfusion of rejuvenated and washed autolgous RBCs
Description: Rejuvenation refers to the process of adding a mix of solutes (Rejuvesol®, Citra Labs, Braintree, MA; consists of sodium pyruvate, inosine, adenine, mono- and dibasic sodium phosphate) to older, stored (i.e., 2-3 DPG-depleted) blood to immediately restore 2,3-DPG and ATP levels in the stored red blood cells15. Rejuvenation was originally developed to prolong the storage life of rare-phenotype RBC units. It is FDA-approved for use in RBC units stored in CPD, CPDA-1, and AS-1. The major contraindication for the use of Rejuvesol® is in RBC units stored for fewer than 6 days due to high baseline 2,3-DPG and ATP levels. Rejuvenated units must be washed prior to administration to remove residual Rejuvesol that is not approved for iv administration in such concentrations.
Study NCT03089047 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Transfusion of washed autolgous RBCs
Description: Autologous RBCs will be washed prior to transfusion to maintain blinding and equalize volume and Hct with the rejuvenated and washed intervention arm
Study NCT00700908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: automated telephone intervention vs. usual care
Study NCT00700908 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: automated telephone intervention vs. usual care
Study NCT02091635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Motilitone)
Description: Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
Study NCT02091635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Motilitone
Description: Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
Study NCT02985177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INF2.0 + IBU
Description: Analgesics
Study NCT02985177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INF1.0 + IBU
Description: Analgesics
Study NCT03853967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose CT scan
Description: low dose CT scan
Study NCT03806530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: 100 mg capsule
Study NCT03806530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 100 mg capsule
Study NCT03806530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole
Description: 0.50 mg capsule
Study NCT03806530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropinirole
Description: 0.50 mg capsule